Regulation of TGFβ and related signals by precursor processing

Seminars in Cell and Developmental Biology

Volumn 32, Issue , 2014, Pages 85-97

  Constam, Daniel B ^a  

^a EPFL   (Switzerland)

Author keywords

BMP; Convertases; DPP precursor; Furin; Latency; Morphogen gradients; Nodal signaling; Proprotein processing; Protein sorting and trafficking

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; PROTEIN; RXXR PROTEIN; SERINE PROTEINASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; PROTEIN BINDING; PROTEIN PRECURSOR;

CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE RELEASE; DNA FLANKING REGION; NONHUMAN; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; PROTEIN TERTIARY STRUCTURE;

ANIMALS; HUMANS; LATENT TGF-BETA BINDING PROTEINS; MODELS, MOLECULAR; PROPROTEIN CONVERTASES; PROTEIN BINDING; PROTEIN PRECURSORS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84904470397     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2014.01.008     Document Type: Review

References (181)

1. Wakefield L.M., Hill C.S. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat Rev Cancer 2013, 13:328-341.
2. Sakaki-Yumoto M., Katsuno Y., Derynck R. TGF-beta family signaling in stem cells. Biochim Biophys Acta 2013, 1830:2280-2296.
3. Akhurst R.J., Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 2012, 11:790-811.
4. Pickup M., Novitskiy S., Moses H.L. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 2013, 13:788-799.
5. Wakefield L.M., Roberts A.B. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002, 12:22-29.
6. Barkai N., Shilo B.Z. Robust generation and decoding of morphogen gradients. Cold Spring Harb Perspect Biol 2009, 1:a001990.
7. Müller P., Rogers K.W., Yu S.R., Brand M., Schier A.F. Morphogen transport. Development 2013, 140:1621-1638.
8. Wharton K.A., Serpe M. Fine-tuned shuttles for bone morphogenetic proteins. Curr Opin Genet Dev 2013, 23:374-384.
9. Plouhinec J.L., Zakin L., De Robertis E.M. Systems control of BMP morphogen flow in vertebrate embryos. Curr Opin Genet Dev 2011, 21:696-703.
10. Shilo B.Z., Haskel-Ittah M., Ben-Zvi D., Schejter E.D., Barkai N. Creating gradients by morphogen shuttling. Trends Genet 2013, 29:339-347.
11. Sneddon J.B., Zhen H.H., Montgomery K., van de Rijn M., Tward A.D., West R., et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A 2006, 103:14842-14847.
12. Tarragona M., Pavlovic M., Arnal-Estape A., Urosevic J., Morales M., Guiu M., et al. Identification of NOG as a specific breast cancer bone metastasis-supporting gene. J Biol Chem 2012, 287:21346-21355.
13. Jaeger E., Leedham S., Lewis A., Segditsas S., Becker M., Cuadrado P.R., et al. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat Genet 2012, 44:699-703.
14. Gao H., Chakraborty G., Lee-Lim AiP, Mo Q., Decker M., Vonica A., et al. The BMP inhibitor coco reactivates breast cancer cells at lung metastatic sites. Cell 2012, 150:764-779.
15. Schlunegger M.P., Grutter M.G. An unusual feature revealed by the crystal structure at 2.2 A resolution of human transforming growth factor-beta 2. Nature 1992, 358:430-434.
16. Shi M., Zhu J., Wang R., Chen X., Mi L., Walz T., et al. Latent TGF-β structure and activation. Nature 2011, 474:343-349.
17. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14:163-176.
18. Munger J.S., Huang X., Kawakatsu H., Griffiths M.J., Dalton S.L., Wu J., et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999, 96:319-328.
19. Aluwihare P., Mu Z., Zhao Z., Yu D., Weinreb P.H., Horan G.S., et al. Mice that lack activity of alphavbeta6- and alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice. J Cell Sci 2009, 122:227-232.
20. Yang Z., Mu Z., Dabovic B., Jurukovski V., Yu D., Sung J., et al. Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J Cell Biol 2007, 176:787-793.
21. Todorovic V., Rifkin D.B. LTBPs, more than just an escort service. J Cell Biochem 2012, 113:410-418.
22. Yoshinaga K., Obata H., Jurukovski V., Mazzieri R., Chen Y., Zilberberg L., et al. Perturbation of transforming growth factor (TGF)-beta1 association with latent TGF-beta binding protein yields inflammation and tumors. Proc Natl Acad Sci U S A 2008, 105:18758-18763.
23. Pereira L., Andrikopoulos K., Tian J., Lee S.Y., Keene D.R., Ono R., et al. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 1997, 17:218-222.
24. Isogai Z., Ono R.N., Ushiro S., Keene D.R., Chen Y., Mazzieri R., et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003, 278:2750-2757.
25. Neptune E.R., Frischmeyer P.A., Arking D.E., Myers L., Bunton T.E., Gayraud B., et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003, 33:407-411.
26. Holm T.M., Habashi J.P., Doyle J.J., Bedja D., Chen Y., van Erp C., et al. Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 2011, 332:358-361.
27. Gregory K.E., Ono R.N., Charbonneau N.L., Kuo C.L., Keene D.R., Bachinger H.P., et al. The prodomain of BMP-7 targets the BMP-7 complex to the extracellular matrix. J Biol Chem 2005, 280:27970-27980.
28. Sengle G., Charbonneau N.L., Ono R.N., Sasaki T., Alvarez J., Keene D.R., et al. Targeting of bone morphogenetic protein growth factor complexes to fibrillin. J Biol Chem 2008, 283:13874-13888.
29. Sengle G., Ono R.N., Sasaki T., Sakai L.Y. Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. J Biol Chem 2011, 286:5087-5099.
30. Yamazaki S., Ema H., Karlsson G., Yamaguchi T., Miyoshi H., Shioda S., et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 2011, 147:1146-1158.
31. Tran D.Q., Andersson J., Wang R., Ramsey H., Unutmaz D., Shevach E.M. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A 2009, 106:13445-13450.
32. Wang R., Zhu J., Dong X., Shi M., Lu C., Springer T.A. GARP regulates the bioavailability and activation of TGFbeta. Mol Biol Cell 2012, 23:1129-1139.
33. Miyazono K., Thyberg J., Heldin C.H. Retention of the transforming growth factor-beta 1 precursor in the Golgi complex in a latent endoglycosidase H-sensitive form. J Biol Chem 1992, 267:5668-5675.
34. Gray A.M., Mason A.J. Requirement for activin A and transforming growth factor-beta 1 pro-regions in homodimer assembly. Science 1990, 247:1328-1330.
35. Sha X., Yang L., Gentry L.E. Identification and analysis of discrete functional domains in the pro region of pre-pro-transforming growth factor beta 1. J Cell Biol 1991, 114:827-839.
36. Walton K.L., Makanji Y., Wilce M.C., Chan K.L., Robertson D.M., Harrison C.A. A common biosynthetic pathway governs the dimerization and secretion of inhibin and related transforming growth factor beta (TGFbeta) ligands. J Biol Chem 2009, 284:9311-9320.
37. Nachtigal M.W., Ingraham H.A. Bioactivation of Mullerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease. Proc Natl Acad Sci U S A 1996, 93:7711-7716.
38. Bauskin A.R., Zhang H.P., Fairlie W.D., He X.Y., Russell P.K., Moore A.G., et al. The propeptide of macrophage inhibitory cytokine (MIC-1), a TGF-beta superfamily member, acts as a quality control determinant for correctly folded MIC-1. EMBO J 2000, 19:2212-2220.
39. Fairlie W.D., Zhang H.P., Wu W.M., Pankhurst S.L., Bauskin A.R., Russell P.K., et al. The propeptide of the transforming growth factor-beta superfamily member, macrophage inhibitory cytokine-1 (MIC-1), is a multifunctional domain that can facilitate protein folding and secretion. J Biol Chem 2001, 276:16911-16918.
40. Le Good J.A., Joubin K., Giraldez A.J., Ben-Haim N., Beck S., Chen Y., et al. Nodal stability determines signaling range. Curr Biol 2005, 15:1-20.
41. Bauskin A.R., Jiang L., Luo X.W., Wu L., Brown D.A., Breit S.N. The TGF-beta superfamily cytokine MIC-1/GDF15: secretory mechanisms facilitate creation of latent stromal stores. J Interferon Cytokine Res 2010, 30:389-397.
42. Brunner A.M., Marquardt H., Malacko A.R., Lioubin M.N., Purchio A.F. Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J Biol Chem 1989, 264:13660-13664.
43. Ben-Haim N., Lu C., Pescatore L., Mesnard D., Bischofberger M., Naef F., et al. The Nodal precursor acting via activin receptors induces mesoderm by maintaining a source of its convertases and BMP4. Dev Cell 2006, 11:1-11.
44. Sengle G., Ono R.N., Lyons K.M., Bachinger H.P., Sakai L.Y. A new model for growth factor activation: type II receptors compete with the prodomain for BMP-7. J Mol Biol 2008, 381:1025-1039.
45. Thies R.S., Chen T., Davies M.V., Tomkinson K.N., Pearson A.A., Shakey Q.A., et al. GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors 2001, 18:251-259.
46. Lee S.J., McPherron A.C. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A 2001, 98:9306-9311.
47. Anderson S.B., Goldberg A.L., Whitman M. Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. J Biol Chem 2008, 283:7027-7035.
48. Sun X., Essalmani R., Susan-Resiga D., Prat A., Seidah N.G. Latent transforming growth factor beta-binding proteins-2 and -3 inhibit the proprotein convertase 5/6A. J Biol Chem 2011, 286:29063-29073.
49. Wolfman N.M., McPherron A.C., Pappano W.N., Davies M.V., Song K., Tomkinson K.N., et al. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci U S A 2003, 100:15842-15846.
50. Ge G., Hopkins D.R., Ho W.-B., Greenspan D.S. GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells. Mol Cell Biol 2005, 25:5846-5858.
51. Kinoshita A., Saito T., Tomita H., Makita Y., Yoshida K., Ghadami M., et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet 2000, 26:19-20.
52. Campos-Xavier B., Saraiva J.M., Savarirayan R., Verloes A., Feingold J., Faivre L., et al. Phenotypic variability at the TGF-beta1 locus in Camurati-Engelmann disease. Hum Genet 2001, 109:653-658.
53. Wu S., Liang S., Yan Y., Wang Y., Li F., Deng Y., et al. A novel mutation of TGF beta1 in a Chinese family with Camurati-Engelmann disease. Bone 2007, 40:1630-1634.
54. Walton K.L., Makanji Y., Chen J., Wilce M.C., Chan K.L., Robertson D.M., et al. Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-beta1 complex. J Biol Chem 2010, 285:17029-17037.
55. Everman D.B., Bartels C.F., Yang Y., Yanamandra N., Goodman F.R., Mendoza-Londono J.R., et al. The mutational spectrum of brachydactyly type C. Am J Med Genet 2002, 112:291-296.
56. Suzuki S., Marazita M.L., Cooper M.E., Miwa N., Hing A., Jugessur A., et al. Mutations in BMP4 are associated with subepithelial, microform, and overt cleft lip. Am J Hum Genet 2009, 84:406-411.
57. Dixit H., Rao L.K., Padmalatha V.V., Kanakavalli M., Deenadayal M., Gupta N., et al. Missense mutations in the BMP15 gene are associated with ovarian failure. Hum Genet 2006, 119:408-415.
58. Imbeaud S., Carre-Eusebe D., Rey R., Belville C., Josso N., Picard J.Y. Molecular genetics of the persistent mullerian duct syndrome: a study of 19 families. Hum Mol Genet 1994, 3:125-131.
59. Belville C., Van Vlijmen H., Ehrenfels C., Pepinsky B., Rezaie A.R., Picard J.Y., et al. Mutations of the anti-mullerian hormone gene in patients with persistent mullerian duct syndrome: biosynthesis, secretion, and processing of the abnormal proteins and analysis using a three-dimensional model. Mol Endocrinol 2004, 18:708-721.
60. Mohapatra B., Casey B., Li H., Ho-Dawson T., Smith L., Fernbach S.D., et al. Identification and functional characterization of NODAL rare variants in heterotaxy and isolated cardiovascular malformations. Hum Mol Genet 2009, 18:861-871.
61. Tian J., Andree B., Jones C.M., Sampath K. The pro-domain of the zebrafish Nodal-related protein Cyclops regulates its signaling activities. Development 2008, 135:2649-2658.
62. Blanchet M.-H., Le Good J.A., Mesnard D., Oorschot V., Baflast S., Minchiotti G., et al. Cripto recruits Furin and PACE4 and controls Nodal trafficking during proteolytic maturation. EMBO J 2008, 27:2580-2591.
63. Wittbrodt J., Rosa F.M. Disruption of mesoderm and axis formation in fish by ectopic expression of activin variants: the role of maternal activin. Genes Dev 1994, 8:1448-1462.
64. Hawley S.H.B., Wünnenberg-Stapleton K., Hashimoto C., Laurent M.N., Watabe T., Blumberg B.W., et al. Disruption of BMP signals in embryonic Xenopus ectoderm leads to direct neural induction. Genes Dev 1995, 9:2923-2935.
65. Osada S.I., Wright C.V. Xenopus nodal-related signaling is essential for mesendodermal patterning during early embryogenesis. Development 1999, 126:3229-3240.
66. Hashimoto O., Moore R.K., Shimasaki S. Posttranslational processing of mouse and human BMP-15: potential implication in the determination of ovulation quota. Proc Natl Acad Sci U S A 2005, 102:5426-5431.
67. Constam D.B., Robertson E.J. Regulation of bone morphogenetic protein activities by pro domains and proprotein convertases. J Cell Biol 1999, 144:139-149.
68. Kunnapuu J., Bjorkgren I., Shimmi O., The Drosophila D.P.P. signal is produced by cleavage of its proprotein at evolutionary diversified furin-recognition sites. Proc Natl Acad Sci U S A 2009, 106:8501-8506.
69. Hatsuzawa K., Nagahama M., Takahashi S., Takada K., Murakami K., Nakayama K. Purification and characterization of furin, a Kex2-like processing endoprotease, produced in Chinese hamster ovary cells. J Biol Chem 1992, 267:16094-16099.
70. Nakayama K. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 1997, 327:625-635.
71. Duckert P., Brunak S., Blom N. Prediction of proprotein convertase cleavage sites. Protein Eng Des Sel 2004, 17:107-112.
72. Remacle A.G., Shiryaev S.A., Oh E.S., Cieplak P., Srinivasan A., Wei G., et al. Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J Biol Chem 2008, 283:20897-20906.
73. Seidah N.G., Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012, 11:367-383.
74. Henrich S., Cameron A., Bourenkov G.P., Kiefersauer R., Huber R., Lindberg I., et al. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol 2003, 10:520-526.
75. Henrich S., Lindberg I., Bode W., Than M.E. Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J Mol Biol 2005, 345:211-227.
76. Couture F., D'Anjou F., Day R. On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomolecular concepts 2011, 2:421-438.
77. Roebroek A.J.M., Umans L., Pauli I.G.L., Robertson E.J., van Leuven F., Van de Ven W.J.M., et al. Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. Development 1998, 125:4863-4876.
78. Constam D.B., Robertson E.J. SPC4/PACE4 regulates a TGFbeta signaling network during axis formation. Genes Dev 2000, 14:1146-1155.
79. Essalmani R., Hamelin J., Marcinkiewicz J., Chamberland A., Mbikay M., Chretien M., et al. Deletion of the gene encoding proprotein convertase 5/6 causes early embryonic lethality in the mouse. Mol Cell Biol 2006, 26:354-361.
80. Essalmani R., Zaid A., Marcinkiewicz J., Chamberland A., Pasquato A., Seidah N.G., et al. In vivo functions of the proprotein convertase PC5/6 during mouse development: Gdf11 is a likely substrate. Proc Natl Acad Sci U S A 2008, 105:5750-5755.
81. Szumska D., Pieles G., Essalmani R., Bilski M., Mesnard D., Kaur K., et al. VACTERL/caudal regression/Currarino syndrome-like malformations in mice with mutation in the proprotein convertase Pcsk5. Genes Dev 2008, 22:1465-1477.
82. Wetsel W.C., Rodriguiz R.M., Guillemot J., Rousselet E., Essalmani R., Kim I.H., et al. Disruption of the expression of the proprotein convertase PC7 reduces BDNF production and affects learning and memory in mice. Proc Natl Acad Sci U S A 2013, 110:17362-17367.
83. Dubois C.M., Laprise M.H., Blanchette F., Gentry L.E., Leduc R. Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 1995, 270:10618-10624.
84. Constam D.B., Calfon M., Robertson E.J. SPC4, SPC6, and the novel protease SPC7 are coexpressed with bone morphogenetic proteins at distinct sites during embryogenesis. J Cell Biol 1996, 134:181-191.
85. Cui Y., Jean F., Thomas G., Christian J.L. BMP-4 is proteolytically activated by furin and/or PC6 during vertebrate embryonic development. EMBO J 1998, 17:4735-4743.
86. Beck S., Le Good J.A., Guzman M., Haim N.B., Roy K., Beermann F., et al. Extraembryonic proteases regulate Nodal signalling during gastrulation. Nat Cell Biol 2002, 4:981-985.
87. Birsoy B., Berg L., Williams P.H., Smith J.C., Wylie C.C., Christian J.L., et al. XPACE4 is a localized pro-protein convertase required for mesoderm induction and the cleavage of specific TGFbeta proteins in Xenopus development. Development 2005, 132:591-602.
88. Nelsen S., Berg L., Wong C., Christian J.L. Proprotein convertase genes in Xenopus development. Dev Dyn 2005, 233:1038-1044.
89. Nelsen S.M., Christian J.L. Site-specific cleavage of BMP4 by furin, PC6 and PC7. J Biol Chem 2009, 284:27157-27166.
90. Mesnard D., Constam D.B. Imaging proprotein convertase activities and their regulation in the implanting mouse blastocyst. J Cell Biol 2010, 191:129-139.
91. van de Loo J.W.H.P., Creemers J.W.M., Bright N.A., Young B.D., Roebroek A.J.M., Van de Ven W.J.M. Biosynthesis, distinct post-translational modifications, and functional characterization of lymphoma proprotein convertase. J Biol Chem 1997, 272:27116-27123.
92. Pesu M., Watford W.T., Wei L., Xu L., Fuss I., Strober W., et al. T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. Nature 2008, 455:246-250.
93. McPherron A.C., Lawler A.M., Lee S.J. Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat Genet 1999, 22:260-264.
94. Susan-Resiga D., Essalmani R., Hamelin J., Asselin M.C., Benjannet S., Chamberland A., et al. Furin is the major processing enzyme of the cardiac-specific growth factor bone morphogenetic protein 10. J Biol Chem 2011, 286:22785-22794.
95. Seidah N.G., Mayer G., Zaid A., Rousselet E., Nassoury N., Poirier S., et al. The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol 2008, 40:1111-1125.
96. De Bie I., Marcinkiewicz M., Malide D., Lazure C., Nakayama K., Bendayan M., et al. The isoforms of proprotein convertase PC5 are sorted to different subcellular compartments. J Cell Biol 1996, 135:1261-1275.
97. Xiang Y., Molloy S.S., Thomas L., Thomas G. The PC6B cytoplasmic domain contains two acidic clusters that direct sorting to distinct trans-Golgi network/endosomal compartments. Mol Biol Cell 2000, 11:1257-1273.
98. Molloy S.S., Anderson E.D., Jean F., Thomas G. Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. Trends Cell Biol 1999, 9:28-35.
99. Mayer G., Boileau G., Bendayan M. Sorting of furin in polarized epithelial and endothelial cells: expression beyond the Golgi apparatus. J Histochem Cytochem 2004, 52:567-579.
100. Rousselet E., Benjannet S., Hamelin J., Canuel M., Seidah N.G. The proprotein convertase PC7: unique zymogen activation and trafficking pathways. J Biol Chem 2010.
101. Vidricaire G., Denault J.B., Leduc R. Characterization of a secreted form of human furin endoprotease. Biochem Biophys Res Commun 1993, 195:1011-1018.
102. Denault J., Bissonnette L., Longpre J., Charest G., Lavigne P., Leduc R. Ectodomain shedding of furin: kinetics and role of the cysteine-rich region. FEBS Lett 2002, 527:309-314.
103. Nour N., Mayer G., Mort J.S., Salvas A., Mbikay M., Morrison C.J., et al. The cysteine-rich domain of the secreted proprotein convertases PC5A and PACE4 functions as a cell surface anchor and interacts with tissue inhibitors of metalloproteinases. Mol Biol Cell 2005, 16:5215-5226.
104. Mayer G., Hamelin J., Asselin M.C., Pasquato A., Marcinkiewicz E., Tang M., et al. The regulated cell surface zymogen activation of the proprotein convertase PC5A directs the processing of its secretory substrates. J Biol Chem 2008, 283:2373-2384.
105. Chapman R.E., Munro S. Retrieval of TGN proteins from the cell surface requires endosomal acidification. EMBO J 1994, 13:2305-2312.
106. Anderson E.D., Molloy S.S., Jean F., Fei H., Shimamura S., Thomas G. The ordered and compartment-specfific autoproteolytic removal of the furin intramolecular chaperone is required for enzyme activation. J Biol Chem 2002, 277:12879-12890.
107. Thomas G. Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002, 3:753-766.
108. Gentry L.E., Lioubin M.N., Purchio A.F., Marquardt H. Molecular events in the processing of recombinant type 1 pre-pro-transforming growth factor beta to the mature polypeptide. Mol Cell Biol 1988, 8:4162-4168.
109. Miyazono K., Olofsson A., Colosetti P., Heldin C.H. A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J 1991, 10:1091-1101.
110. Sha X., Brunner A.M., Purchio A.F., Gentry L.E. Transforming growth factor beta 1: importance of glycosylation and acidic proteases for processing and secretion. Mol Endocrinol 1989, 3:1090-1098.
111. Massague J., Kelly B. Internalization of transforming growth factor-beta and its receptor in BALB/c 3T3 fibroblasts. J Cell Physiol 1986, 128:216-222.
112. Lonka-Nevalaita L., Lume M., Leppanen S., Jokitalo E., Peranen J., Saarma M. Characterization of the intracellular localization, processing, and secretion of two glial cell line-derived neurotrophic factor splice isoforms. J Neurosci 2010, 30:11403-11413.
113. Moore A.G., Brown D.A., Fairlie W.D., Bauskin A.R., Brown P.K., Munier M.L., et al. The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab 2000, 85:4781-4788.
114. Brown D.A., Lindmark F., Stattin P., Balter K., Adami H.O., Zheng S.L., et al. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res 2009, 15:6658-6664.
115. Johnen H., Lin S., Kuffner T., Brown D.A., Tsai V.W., Bauskin A.R., et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 2007, 13:1333-1340.
116. Bauskin A.R., Brown D.A., Junankar S., Rasiah K.K., Eggleton S., Hunter M., et al. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res 2005, 65:2330-2336.
117. Olofsson A., Hellman U., Ten Dijke P., Grimsby S., Ichijo H., Moren A., et al. Latent transforming growth factor-beta complex in Chinese hamster ovary cells contains the multifunctional cysteine-rich fibroblast growth factor receptor, also termed E-selectin-ligand or MG-160. Biochem J 1997, 324(Pt 2):427-434.
118. Yang T., Mendoza-Londono R., Lu H., Tao J., Li K., Keller B., et al. E-selectin ligand-1 regulates growth plate homeostasis in mice by inhibiting the intracellular processing and secretion of mature TGF-beta. J Clin Invest 2010, 120:2474-2485.
119. Antoine M., Kohl R., Tag C.G., Gressner A.M., Hellerbrand C., Kiefer P. Secreted cysteine-rich FGF receptor derives from posttranslational processing by furin-like prohormone convertases. Biochem Biophys Res Commun 2009, 382:359-364.
120. Miyaoka Y., Kato H., Ebato K., Saito S., Miyata N., Imamura T., et al. Retention in the Golgi apparatus and expression on the cell surface of Cfr/Esl-1/Glg-1/MG-160 are regulated by two distinct mechanisms. Biochem J 2011, 440:33-41.
121. Zacchigna L., Vecchione C., Notte A., Cordenonsi M., Dupont S., Maretto S., et al. Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell 2006, 124:929-942.
122. Bressan G.M., Daga-Gordini D., Colombatti A., Castellani I., Marigo V., Volpin D. Emilin, a component of elastic fibers preferentially located at the elastin-microfibrils interface. J Cell Biol 1993, 121:201-212.
123. Chi Z., Zhang J., Tokunaga A., Harraz M.M., Byrne S.T., Dolinko A., et al. Botch promotes neurogenesis by antagonizing Notch. Dev Cell 2012.
124. Schier A.F. Nodal signaling in vertebrate development. Annu Rev Cell Dev Biol 2003, 19:589-621.
125. Brennan J., Lu C.C., Norris D.P., Rodriguez T.A., Beddington R.S., Robertson E.J. Nodal signalling in the epiblast patterns the early mouse embryo. Nature 2001, 411:965-969.
126. Camus A., Perea-Gomez A., Moreau A., Collignon J. Absence of Nodal signaling promotes precocious neural differentiation in the mouse embryo. Dev Biol 2006, 295:743-755.
127. Mesnard D., Guzman-Ayala M., Constam D.B. Nodal specifies embryonic visceral endoderm and sustains pluripotent cells in the epiblast before overt axial patterning. Development 2006, 133:2497-2505.
128. Vallier L., Reynolds D., Pedersen R.A. Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. Dev Biol 2004, 275:403-421.
129. James D., Levine A.J., Besser D., Hemmati-Brivanlou A. TGFß/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 2005, 132:1273-1282.
130. Vallier L., Mendjan S., Brown S., Chng Z., Teo A., Smithers L.E., et al. Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. Development 2009, 136:1339-1349.
131. Spiller C.M., Feng C.W., Jackson A., Gillis A.J., Rolland A.D., Looijenga L.H., et al. Endogenous Nodal signaling regulates germ cell potency during mammalian testis development. Development 2012, 139:4123-4132.
132. Souquet B., Tourpin S., Messiaen S., Moison D., Habert R., Livera G. Nodal signaling regulates the entry into meiosis in fetal germ cells. Endocrinology 2012.
133. Wu Q., Kanata K., Saba R., Deng C.X., Hamada H., Saga Y. Nodal/activin signaling promotes male germ cell fate and suppresses female programming in somatic cells. Development 2013, 140:291-300.
134. Varlet I., Collignon J., Robertson E.J. Nodal expression in the primitive endoderm is required for specification of the anterior axis during mouse gastrulation. Development 1997, 124:1033-1044.
135. Shen M.M. Nodal signaling: developmental roles and regulation. Development 2007, 134:1023-1034.
136. Watanabe K., Hamada S., Bianco C., Mancino M., Nagaoka T., Gonzales M., et al. Requirement of glycosylphosphatidylinositol anchor of cripto-1 for 'trans' activity as a nodal co-receptor. J Biol Chem 2007, 282:35772-35786.
137. Yan Y.T., Liu J.J., Luo Y., Chaosu E., Haltiwanger R.S., Abate-Shen C., et al. Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway. Mol Cell Biol 2002, 22:4439-4449.
138. Blanchet M.-H., Le Good J.A., Oorschot V., Baflast S., Minchiotti G., Klumperman J., et al. Cripto localizes Nodal at the limiting membrane of early endosomes. Sci Signal 2008, 1:ra13.
139. Constam D.B. Running the gauntlet: an overview of the modalities of travel employed by the putative morphogen Nodal. Curr Opin Genet Dev 2009, 19:302-307.
140. Constam D.B. Riding shotgun: a dual role for the epidermal growth factor-Cripto/FRL-1/Cryptic protein Cripto in Nodal trafficking. Traffic 2009, 10:783-791.
141. Mesnard D., Donnison M., Fuerer C., Pfeffer P.L., Constam D.B. The microenvironment patterns the pluripotent mouse epiblast through paracrine Furin and Pace4 proteolytic activities. Genes Dev 2011, 25:1871-1880.
142. Kwon S., Christian J.L. Sortilin associates with TGF-β family proteins to enhance lysosome-mediated degradation. J Biol Chem 2011, 286:21876-21885.
143. Eimon P.M., Harland R.M. Effects of heterodimerization and proteolytic processing on Derriere and Nodal activity: implications for mesoderm induction in Xenopus. Development 2002, 129:3089-3103.
144. Sampath K., Cheng A.M., Frisch A., Wright C.V. Functional differences among Xenopus nodal-related genes in left-right axis determination. Development 1997, 124:3293-3302.
145. Chen Y., Schier A.F. The zebrafish Nodal signal Squint functions as a morphogen. Nature 2001, 411:607-610.
146. Cheng S.K., Olale F., Brivanlou A.H., Schier A.F. Lefty blocks a subset of TGFbeta signals by antagonizing EGF-CFC coreceptors. PLoS Biol 2004, 2:E30.
147. Muller P., Rogers K.W., Jordan B.M., Lee J.S., Robson D., Ramanathan S., et al. Differential diffusivity of nodal and lefty underlies a reaction-diffusion patterning system. Science 2012.
148. Affolter M., Basler K. The Decapentaplegic morphogen gradient: from pattern formation to growth regulation. Nat Rev Genet 2007, 8:663-674.
149. Lecuit T., Cohen S.M. Dpp receptor levels contribute to shaping the Dpp morphogen gradient in the Drosophila wing imaginal disc. Development 1998, 125:4901-4907.
150. Tanimoto H., Itoh S., ten Dijke P., Tabata T. Hedgehog creates a gradient of DPP activity in Drosophila wing imaginal discs. Mol Cell 2000, 5:59-71.
151. Teleman A.A., Cohen S.M. Dpp gradient formation in the Drosophila wing imaginal disc. Cell 2000, 103:971-980.
152. Entchev E.V., Schwabedissen A., Gonzalez-Gaitan M. Gradient formation of the TGF-beta homolog Dpp. Cell 2000, 103:981-991.
153. Kicheva A., Pantazis P., Bollenbach T., Kalaidzidis Y., Bittig T., Julicher F., et al. Kinetics of morphogen gradient formation. Science 2007, 315:521-525.
154. Schwank G., Dalessi S., Yang S.F., Yagi R., de Lachapelle A.M., Affolter M., et al. Formation of the long range dpp morphogen gradient. PLoS Biol 2011, 9:e1001111.
155. Zhou S., Lo W.C., Suhalim J.L., Digman M.A., Gratton E., Nie Q., et al. Free extracellular diffusion creates the Dpp morphogen gradient of the drosophila wing disc. Curr Biol 2012.
156. Gibson M.C., Lehman D.A., Schubiger G. Lumenal transmission of decapentaplegic in Drosophila imaginal discs. Dev Cell 2002, 3:451-460.
157. Akiyama T., Kamimura K., Firkus C., Takeo S., Shimmi O., Nakato H. Dally regulates Dpp morphogen gradient formation by stabilizing Dpp on the cell surface. Dev Biol 2008, 313:408-419.
158. Jackson S.M., Nakato H., Sugiura M., Jannuzi A., Oakes R., Kaluza V., et al. Dally, a Drosophila glypican, controls cellular responses to the TGF-beta-related morphogen, Dpp. Development 1997, 124:4113-4120.
159. Fujise M., Takeo S., Kamimura K., Matsuo T., Aigaki T., Izumi S., et al. Dally regulates Dpp morphogen gradient formation in the Drosophila wing. Development 2003, 130:1515-1522.
160. Belenkaya T.Y., Han C., Yan D., Opoka R.J., Khodoun M., Liu H., et al. Drosophila Dpp morphogen movement is independent of dynamin-mediated endocytosis but regulated by the glypican members of heparan sulfate proteoglycans. Cell 2004, 119:231-244.
161. Takei Y., Ozawa Y., Sato M., Watanabe A., Tabata T., Three Drosophila E.X.T. genes shape morphogen gradients through synthesis of heparan sulfate proteoglycans. Development 2004, 131:73-82.
162. Koenig B.B., Cook J.S., Wolsing D.H., Ting J., Tiesman J.P., Correa P.E., et al. Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol Cell Biol 1994, 14:5961-5974.
163. Ruppert R., Hoffmann E., Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 1996, 237:295-302.
164. Jiao X., Billings P.C., O'Connell M.P., Kaplan F.S., Shore E.M., Glaser D.L. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem 2007, 282:1080-1086.
165. Oki S., Hashimoto R., Okui Y., Shen M.M., Mekada E., Otani H., et al. Sulfated glycosaminoglycans are necessary for Nodal signal transmission from the node to the left lateral plate in the mouse embryo. Development 2007, 134:3893-3904.
166. Li S., Shimono C., Norioka N., Nakano I., Okubo T., Yagi Y., et al. Activin a binds to perlecan through its pro-region that has heparin/heparan sulfate-binding activity. J Biol Chem 2010.
167. Cui Y., Hackenmiller R., Berg L., Jean F., Nakayama T., Thomas G., et al. The activity and signaling range of mature BMP-4 is regulated by sequential cleavage at two sites within the prodomain of the precursor. Genes Dev 2001, 15:2797-2802.
168. Goldman D.C., Hackenmiller R., Nakayama T., Sopory S., Wong C., Kulessa H., et al. Mutation of an upstream cleavage site in the BMP4 prodomain leads to tissue-specific loss of activity. Development 2006, 133:1933-1942.
169. Degnin C., Jean F., Thomas G., Christian J.L. Cleavages within the prodomain direct intracellular trafficking and degradation of mature BMP-4. Mol Biol Cell 2004, 15:5012-5020.
170. Sopory S., Kwon S., Wehrli M., Christian J.L. Regulation of Dpp activity by tissue-specific cleavage of an upstream site within the prodomain. Dev Biol 2010.
171. Akiyama T., Marques G., Wharton K.A. A large bioactive BMP ligand with distinct signaling properties is produced by alternative proconvertase processing. Sci Signal 2012, 5:ra28.
172. Fritsch C., Sawala A., Harris R., Maartens A., Sutcliffe C., Ashe H.L., et al. Different requirements for proteolytic processing of bone morphogenetic protein 5/6/7/8 ligands in Drosophila melanogaster. J Biol Chem 2012, 287:5942-5953.
173. Peterson A.J., O'Connor M.B. You're going to need a bigger (Glass Bottom). Boat Sci Signal 2012, 5:pe14.
174. Meno C., Saijoh Y., Fujii H., Ikeda M., Yokoyama T., Yokoyama M., et al. Left-right asymmetric expression of the TGF beta-family member lefty in mouse embryos. Nature 1996, 381:151-155.
175. Guzman-Ayala M., Ben-Haim N., Beck S., Constam D.B. Nodal protein processing and fibroblast growth factor-4 synergize to maintain a trophoblast stem cell microenvironment. Proc Natl Acad Sci U S A 2004, 101:15656-15660.
176. Blanchette F., Rudd P., Grondin F., Attisano L., Dubois C.M. Involvement of Smads in TGFbeta1-induced furin (fur) transcription. J Cell Physiol 2001, 188:264-273.
177. Dogar A.M., Towbin H., Hall J. Suppression of latent TGF-beta1 restores growth inhibitory TGF-beta signaling through microRNAs. J Biol Chem 2011.
178. Dillon S.L., Williamson D.M., Elferich J., Radler D., Joshi R., Thomas G., et al. Propeptides are sufficient to regulate organelle-specific pH-dependent activation of furin and proprotein convertase 1/3. J Mol Biol 2012.
179. Munck Petersen C., Nielsen M.S., Jacobsen C., Tauris J., Jacobsen L., Gliemann J., et al. Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding. EMBO J 1999, 18:595-604.
180. Huylebroeck D., Van N.K., Waheed A., von F.K., Marmenout A., Fransen L., et al. Expression and processing of the activin-A/erythroid differentiation factor precursor: a member of the transforming growth factor-beta superfamily. Mol Endocrinol 1990, 4:1153-1165.
181. Brown M.A., Zhao Q., Baker K.A., Naik C., Chen C., Pukac L., et al. Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem 2005, 280:25111-25118.